Non-scarring hair loss is one of the most common reasons people seek dermatological advice in the UK, affecting millions across all age groups. Unlike scarring alopecia, non-scarring forms preserve the hair follicle, meaning regrowth is often possible with the right diagnosis and treatment. Conditions such as androgenetic alopecia, telogen effluvium, and alopecia areata each have distinct causes, presentations, and management pathways. This article explains how non-scarring hair loss is classified, what causes it, which treatments are available on the NHS and privately, and when to seek medical advice.

What Is Non-Scarring Hair Loss and How Is It Classified?

Non-scarring hair loss preserves the hair follicle, allowing potential regrowth, and is classified as diffuse, patterned, or patchy based on distribution. Diagnosis relies on clinical history, scalp examination, and tests such as dermoscopy or the hair pull test.

Not sure if this is normal? Chat with one of our pharmacists →

Non-scarring hair loss refers to a group of conditions in which hair is lost without permanent destruction of the hair follicle. Unlike scarring (cicatricial) alopecia, where follicles are irreversibly damaged and replaced by fibrous tissue, non-scarring hair loss preserves the follicular architecture. This means that, in many cases, hair regrowth is possible once the underlying cause is identified and addressed — though the degree of recovery varies depending on the cause and how long the condition has been present.

Dermatologists classify non-scarring hair loss into three broad presentations:

• Diffuse hair loss: widespread thinning across the scalp, as seen in telogen effluvium

• Patterned hair loss: a predictable distribution affecting the crown and temples, characteristic of androgenetic alopecia

• Patchy (focal) hair loss: well-demarcated areas of hair loss, as seen in alopecia areata or traction alopecia

Diagnosis typically involves a thorough clinical history, scalp examination, and — where appropriate — bedside tests such as the hair pull test, dermoscopy, or trichoscopy. Targeted blood tests may also be arranged. Key features that help distinguish non-scarring from scarring alopecia include:

• Preserved follicular ostia (visible pore openings on the scalp)

• Absence of scarring, atrophy, perifollicular erythema, or significant inflammation on examination

• Potential for hair regrowth, which varies by cause and chronicity

Understanding the classification is clinically important because it directly guides investigation and management. A correct diagnosis ensures patients receive appropriate treatment rather than interventions that may be ineffective or unnecessary. NICE CKS and the NHS provide patient-facing guidance on the initial assessment of hair loss.

Common Causes of Non-Scarring Hair Loss in the UK

Androgenetic alopecia is the most prevalent cause, affecting around 50% of men by age 50, followed by telogen effluvium, alopecia areata, and less common causes such as tinea capitis and trichotillomania. Underlying triggers such as iron deficiency, thyroid dysfunction, and certain medications should be identified and addressed.

Several conditions account for the majority of non-scarring hair loss presentations seen in UK primary and secondary care. The most prevalent is androgenetic alopecia (male- or female-pattern hair loss), which affects approximately 50% of men by the age of 50 and a significant proportion of women, particularly after the menopause. It is driven by the action of dihydrotestosterone (DHT) on genetically susceptible follicles, causing progressive miniaturisation.

Telogen effluvium is another common cause, characterised by diffuse shedding triggered by a physiological stressor. Recognised triggers include:

• Significant illness or surgery

• Childbirth (postpartum telogen effluvium)

• Rapid weight loss

• Iron deficiency (identified by low serum ferritin)

• Psychological stress

• Thyroid dysfunction

• Certain medications (including retinoids, beta-blockers, anticoagulants, and some thyroid drugs)

Zinc and vitamin D deficiency have been proposed as contributing factors, but the evidence base is less established; testing for these is only appropriate where clinically indicated. In telogen effluvium, a large proportion of hairs are prematurely shifted into the resting (telogen) phase, leading to noticeable shedding two to three months after the precipitating event. The condition is usually self-limiting.

Alopecia areata is an autoimmune condition causing well-demarcated, patchy hair loss. It affects around 2% of the UK population at some point in their lifetime and can involve the scalp, eyebrows, eyelashes, and body hair. In some individuals, it progresses to alopecia totalis (complete scalp hair loss) or alopecia universalis (total body hair loss).

Anagen effluvium — abrupt shedding of actively growing hairs — is most commonly caused by chemotherapy or other cytotoxic agents and differs from telogen effluvium in its mechanism and time course.

Trichotillomania is a hair-pulling disorder that can present with irregular, patchy hair loss and should be considered, particularly in children and young people.

Other causes include tinea capitis (a fungal scalp infection more common in children, requiring systemic antifungal treatment), traction alopecia from hairstyling practices, and hair loss associated with systemic conditions such as lupus erythematosus or polycystic ovary syndrome (PCOS). In women with PCOS, clinical features of hyperandrogenism — such as acne, hirsutism, or menstrual irregularity — may help guide further investigation.

Treatment Options Available on the NHS and Privately

Topical minoxidil is available over the counter for androgenetic alopecia, while finasteride is typically prescribed privately in England due to NHS commissioning restrictions. JAK inhibitors baricitinib and ritlecitinib are now licensed for severe alopecia areata and accessible on the NHS under NICE criteria.

Treatment for non-scarring hair loss depends on the underlying cause, severity, and patient preference. It is important to set realistic expectations, as responses to treatment vary considerably between individuals.

For androgenetic alopecia, the two most established treatments are:

• Minoxidil (topical): Topical minoxidil 2% and 5% solutions or foam are available over the counter in the UK without a prescription. Minoxidil prolongs the anagen (growth) phase of the hair cycle and increases follicular size; it is licensed for use in both men and women. Oral low-dose minoxidil is increasingly used but is not licensed for hair loss in the UK and is therefore prescribed off-label on a private prescription only. It carries cardiovascular risks (including fluid retention and hypotension) and should only be initiated and monitored by a clinician experienced in its use, with blood pressure assessment before and during treatment.

• Finasteride (oral, 1 mg daily): A 5-alpha reductase inhibitor that reduces DHT levels. Finasteride is licensed for male-pattern hair loss in the UK; however, in England it is generally not routinely commissioned on the NHS for this indication and is typically prescribed privately. Commissioning policies vary across Integrated Care Boards (ICBs), and patients should check with their GP or local ICB. Important safety information: The MHRA 2024 Drug Safety Update highlights that finasteride is associated with risks of depression, suicidal ideation, and sexual dysfunction (including ejaculatory and erectile dysfunction), which may persist after stopping the medicine. Patients should be issued a patient alert card and advised to seek medical attention promptly if they experience mood changes or persistent sexual side effects. Finasteride is contraindicated in pregnancy and must not be handled by women who are pregnant or may become pregnant, as absorption through broken or crushed tablets poses a risk of harm to a male foetus. Suspected side effects should be reported via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

Finasteride is not recommended for women of childbearing potential. In women with female-pattern hair loss, spironolactone (off-label) may be considered in specialist settings. Hair transplantation is an option for selected patients with stable androgenetic alopecia and is available privately.

For alopecia areata, NICE and the British Association of Dermatologists (BAD) support the use of potent topical corticosteroids as first-line treatment for limited disease. Intralesional corticosteroid injections may be offered in secondary care. Two JAK inhibitors are now licensed in the UK for severe alopecia areata in adults:

• Baricitinib: received MHRA approval and is available on the NHS in England subject to NICE Technology Appraisal criteria, for use in specialist settings with appropriate monitoring

• Ritlecitinib: also licensed in the UK for adults and adolescents aged 12 and over with severe alopecia areata, with NHS access governed by NICE Technology Appraisal criteria

Both agents are initiated and monitored by specialists, and patients should receive appropriate risk counselling before starting treatment.

For telogen effluvium, management focuses on identifying and correcting the underlying trigger — for example, optimising thyroid function or addressing iron deficiency. No specific licensed pharmacological treatment exists for this condition. Privately, patients may access platelet-rich plasma (PRP) therapy or low-level laser therapy, though evidence for these remains limited and they are not routinely available on the NHS.

When to See a GP or Dermatologist About Hair Loss

You should see your GP if hair loss is sudden, patchy, or accompanied by scalp changes, systemic symptoms, or significant distress. Prompt specialist referral is warranted if scarring alopecia is suspected or first-line treatments have failed.

Many people experiencing hair loss delay seeking medical advice, often attributing it to normal ageing or stress. However, timely assessment is important, particularly when hair loss is rapid, extensive, or accompanied by other symptoms.

You should contact your GP if you notice:

• Sudden or patchy hair loss that develops over a short period

• Hair loss accompanied by scalp redness, scaling, itching, or pain

• Associated symptoms such as fatigue, weight changes, or irregular periods, which may suggest an underlying systemic condition

• Hair loss in children, which warrants prompt evaluation to exclude tinea capitis (a contagious fungal infection requiring systemic antifungal treatment and, where relevant, advice regarding school or nursery attendance) or alopecia areata

• Significant psychological distress related to hair loss, which may benefit from early support

Your GP will typically take a detailed history and may arrange blood tests to exclude common medical causes. In line with UK primary care guidance (NICE CKS), first-line investigations usually include a full blood count, serum ferritin, and thyroid function tests (TSH). Additional tests — such as vitamin D, zinc, androgens, or prolactin — are only arranged where clinically indicated by the history and examination findings, not as a matter of routine.

Signs that may suggest scarring alopecia and warrant prompt specialist referral include:

• Loss of visible follicular openings on the scalp

• Shiny, atrophic, or scarred scalp skin

• Pustules or perifollicular erythema

• Rapidly progressive or irreversible-appearing hair loss

Referral to a consultant dermatologist is advisable when the diagnosis is uncertain, when first-line treatments have failed, or when scarring alopecia cannot be excluded. Dermatologists have access to dermoscopy and, where necessary, scalp biopsy — a key investigation for distinguishing non-scarring from scarring conditions. In the UK, referrals can be made via the NHS e-Referral Service, though waiting times vary by region. Private dermatology appointments offer faster access for those who are able to self-fund.

Managing Hair Loss: Outlook and Practical Support

Telogen effluvium usually resolves within six to twelve months; androgenetic alopecia is progressive but can be stabilised with early treatment. Psychological support, camouflage options, and NHS wig provision are important components of holistic care.

The prognosis for non-scarring hair loss varies considerably depending on the underlying cause. Telogen effluvium typically resolves within six to twelve months once the precipitating factor is addressed, and full regrowth is usually expected. Androgenetic alopecia is a progressive condition, but early intervention with minoxidil or finasteride can slow or stabilise hair loss in many patients. Alopecia areata follows an unpredictable course — spontaneous regrowth occurs in a significant proportion of those with limited patchy disease, though relapse is common and outcomes are less favourable in those with extensive, long-standing, or early-onset alopecia. Patients should be counselled that regrowth rates vary and that recurrence is possible even after apparent recovery.

Beyond medical treatment, practical measures can help patients manage the impact of hair loss on daily life:

• Gentle hair care: Avoiding excessive heat styling, tight hairstyles, and harsh chemical treatments reduces additional mechanical stress on fragile hair

• Nutritional support: Ensuring adequate intake of protein, iron, and key micronutrients supports overall hair health; supplements should only be taken where a deficiency has been confirmed, as routine supplementation without deficiency is not supported by current evidence

• Camouflage options: Scalp micropigmentation, hair fibres, wigs, and hairpieces are practical options for those seeking cosmetic solutions

Regarding NHS wig provision: eligibility and charges differ across the UK nations. In England, wigs are available on the NHS for eligible patients (including those with alopecia areata), but a prescription charge applies unless the patient is exempt. In Scotland and Wales, NHS wigs are generally provided free of charge. Patients should speak to their GP or dermatologist about local provision, and Alopecia UK — a national charity — provides up-to-date guidance on wig access and funding alongside peer support and information resources.

The psychological impact of hair loss — particularly in women and young people — should not be underestimated. Studies consistently show associations between hair loss and reduced self-esteem, anxiety, and depression. Patients experiencing significant distress should be signposted to appropriate support, including Alopecia UK, or referred for psychological therapies via their GP. A compassionate, holistic approach to care remains central to good clinical practice in this area.

Frequently Asked Questions